Catalyst Brief

← Calendar

Readoutin 135d

Almirall, S.A. — Lebrikizumab

Phase 3 primary completion: A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis.

Date
Apr 2027
Type
Readout
Indication
Dermatitis, Atopic

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.